UNIVERSITY OF FLORIDA

BioCardia's CardiAMP Cell Therapy demonstrated an 82% reduction in angina episodes and 80-second improvement in exercise tolerance at six months in patients with chronic myocardial ischemia.

Applied Cognition published a groundbreaking study in Nature Biomedical Engineering demonstrating the first continuous, non-invasive measurement of human glymphatic function using novel electrical impedance spectroscopy technology.

Tryptamine Therapeutics and Swinburne University have signed an agreement to conduct the world's first clinical trial using intravenous psilocin (TRP-8803) to treat Binge Eating Disorder, with recruitment beginning this quarter.

Gene therapy is transforming treatment for neuromuscular diseases, with AAV-mediated approaches offering multiple strategies including adding, silencing, or editing genes depending on disease mechanisms.

A major study of 30,000 patients demonstrates that GLP-1 receptor agonists like Ozempic and Wegovy may have significant antidepressant effects, opening new therapeutic possibilities.

BioCardia has completed enrollment and dosing of the low-dose cohort in its CardiALLO Phase I/II trial, targeting ischemic heart failure patients with elevated markers of heart stress and inflammation.

A rigorous 96-week Phase 3 trial involving 194 Parkinson's patients across six UK hospitals found that exenatide, a GLP-1 drug related to Ozempic, showed no benefit in treating or slowing disease progression.

A retrospective Medicare study found GLP-1 receptor agonists associated with 40% lower mortality risk compared to DPP4 inhibitors in older cancer patients with type 2 diabetes.

A personalized mRNA vaccine developed at the University of Florida triggered a strong immune response against glioblastoma within 48 hours in a first-ever human clinical trial of four patients.